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Introduction: Cell-based therapy represents a new frontier in the treatment of a wide variety of human diseases
traditionally associated with morbidity outcomes, including those involving inflammation, autoimmunity, tissue
damage, and cancer. However, the use of mesenchymal stem cells (MSCs) to treat multiple myeloma (MM) bone
disease has raised concerns. Specifically, evidence has shown that infused MSCs might support tumor growth and
metastasis.
Methods: In this study, we used a standard disseminated MM model in mice to identify the in vivo effects of
intravenous MSC infusion. In addition, a series of in vitro co-culture assays were preformed to explore whether
Fas/Fas ligand (Fas-L) is involved in the inhibitory effects of MSCs on MM cells.
Results: In the MM mouse model, treatment of MSCs with highly expressed Fas ligand (Fas-Lhigh MSCs) showed
remarkable inhibitory effects on MM indenization in terms of extending the mouse survival rate and inhibiting
tumor growth, bone resorption in the lumbus and collum femoris, and MM cell metastasis in the lungs and kidneys.
In addition, reduced proliferation and increased apoptosis of MM cells was observed when co-cultured with
Fas-Lhigh MSCs in vitro. Furthermore, mechanistically, the binding between Fas and Fas-L significantly induced
apoptosis in MM cells, as evidenced through an increase in the expression of apoptosis marker and Fas in MM cells.
In contrast, Fas-Lnull MSCs promote MM growth.
Conclusions: These data suggest that Fas/Fas-L-induced MM apoptosis plays a crucial role in the MSC-based
inhibition of MM growth. Although whether MSCs inhibit or promote cancer growth remains controversial, the
levels of Fas-L expression in MSCs determine, at least partially, the effects of MSCs on MM cell growth.Introduction
Multiple myeloma (MM) is the second most common
hematological malignancy, with a yearly incidence of 14,000
in the United States, constituting 13% of blood cancers and
1% of all human cancers [1]. MM is unique among most
hematological malignancies, with a high capacity to in-
duce osteolytic bone lesions through the suppression
of osteoblastogenesis, stimulation of osteoclastogenesis
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reproduction in any medium, provided the orbone formation in areas adjacent to tumor foci in the
bone marrow [2]. The occurrence of bone lesions is
thus one of the major characteristics of MM patients
[3]; the number of osteolytic or focal lesions has been
associated with clinical disease progression for patients
with MM [4]. More than 80% of MM patients suffer from
large osteolytic lesions, and a lack of clinically effective
therapeutics leads to the increasing severity of skeletal
complications and, indeed, death as a result of lowered
resistance to infection (that is, immunodeficiency), hyper-
calcemia, anemia, and renal failure, among others [5]. It is
estimated that MM, with a median overall survival of 3
to 5 years, accounts for approximately 20% of deaths
from hematologic malignancy and 1 to 2% of cancer-related
deaths overall [6]. Currently, cure is a realistic goal for onlyLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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mortality rates associated with plasma cell malignancy have
led to an increased demand for the effective management
of this condition.
It is now generally accepted that MM bone disease is a
reflection of osteoblast deactivation [3,7]. The correc-
tion of osteoblast function in the bone of MM patients,
therefore, has long been a primary target for the design
of therapeutics for MM-related bone disease. To this
end, bisphosphonates, such as pamidronate, and novel
agents, such as lenalidomide, dasatinib, and bortezomib,
which inhibit osteoclast activity and/or activate osteoblasts,
have been identified for treatment of MM-induced
osteoblast deactivation [2,8]. Increased knowledge of
the signaling pathways involved in the regulation of
osteoblast formation and differentiation from MSCs might
provide a better understanding of the pathophysiological
mechanisms involved in MM-induced osteoblast inhibition
and permit the development of more potential therapeutic
agents against bone damage [2,8,9]. In this regard, novel
osteoblast-activating agents, such as dickkopf-1-neutralizing
antibody [10] and inhibitor of activin A signaling [11], are
explored for the clinical treatment of MM bone disease.
The combination of traditional cytotoxic and novel agents
has led to higher response rates and improved long-term
survival compared with treatment with standard doses
of chemotherapy alone. Unfortunately, not all patients
will respond to established novel agents, and even those
who do respond will ultimately relapse or become re-
fractory to currently available regimens. Moreover, large
lytic lesions are typically not repaired, even after long-
term remission, and relapses often occur in pre-existing
lesions [4]. Consequently, additional approaches are ur-
gently needed to achieve systemic bone anabolism and
repair large osteolytic lesions.
The use of mesenchymal stem cells (MSCs), also called
mesenchymal stem cells, to treat MM bone disease has
received considerable attention in the field of stem cell
research [12]. However, whether MSC infusion inhibits
or promotes cancer growth remains controversial. A
number of in vitro studies suggest that MSCs from
MM patients possess abnormal genomic, phenotypic,
and functional properties, which might contribute to
impaired bone formation in this disease by supporting and
protecting MM cells from spontaneous and drug-induced
apoptosis [9]. Furthermore, recent evidence shows that
MSCs, when injected subcutaneously, promote tumor
growth and neovascularization in syngeneic mouse
models through directly supporting the tumor vasculature
and secreting proangiogenic factors [13]. Indeed, the
promotion of tumor growth through MSCs has also
been observed in various cancer models (reviewed in [14]),
suggesting that, at least in some specific conditions,
MSCs play important roles in tumor progression.In contrast with evidence supporting the fact that
MSCs stimulate tumor growth, other studies have
documented the routine suppression of tumor growth
through MSCs (also reviewed in [14]). In particular,
exogenously administered MSCs effectively promote bone
formation and inhibit bone disease and the growth of
highly aggressive MM cells in the bone, although the
majority of systemically injected MSCs were localized in
the lungs or in draining lymph nodes [15]. Furthermore,
intrabone-injected MSCs have been demonstrated to act
as bystander cells to promote bone formation, inhibit
osteolysis, and delay MM growth and regrowth [5,15].
New insights into the effects of in vivo milieu on MSC
functions might explain these contradicting results [16,17].
Notably, a high dose of melphalan with autologous stem
cell support has played an integral part in MM therapy for
more than 25 years, either as salvage therapy or to consoli-
date initial remission, although these therapeutic regimens
typically utilize MM cells as adjuvants for other therapeutic
agents [12]. Moreover, after MSC transplantation in over
1,000 patients with a clinically acceptable safety profile, not
a single case of MSC-related tumors has been reported in a
variety of indications [14]. Conceptually, it is a small leap
from the adjuvant use of stem cells to novel cell-based ther-
apies to enhance the therapeutic outcome of MM, but the
idea has only recently begun to gain momentum.
The clinical and molecular characteristics of MM-related
osteolytic lesions support the potential success of cell-based
therapies for this disease [5,12,15], where the exogenous
administration of healthy MSCs might affect MM bone
disease via the secretion of trophic factors, instead of, or
in addition to, directly participating in the regeneration
of the damaged bone [12]. Gunn and colleagues showed
that an interaction between MM cells and MSCs from
the bone marrow stroma stimulated the production
of dickkopf-1 and IL-6, resulting in the formation
and persistence of osteolytic bone lesions [18]. These
authors also showed that the Wnt signaling activator
6-bromoindirubin-3′-monoxime might release MSCs
from the osteoinhibitory effects of Dickkopf-1, enabling
released MSCs to repair existing osteolytic lesions [18].
Following the adjuvant use of stem cells for MM therapy
[12], Li and colleagues proposed a proof-of-concept
that healthy MSCs, independent of other therapeutic
agents, might attenuate the growth of MM and sup-
press MM-induced bone disease through the inhibition
of osteoclastogenesis and stimulation of endogenous
osteoblastogenesis [5,15]. Taken together, these data lead
to new insights into, and the further exploration of, stem
cell-based therapeutics for MM patients.
In addition to altering the bone marrow milieu that
favors MM cell accommodation, the therapeutic effects of
exogenously infused MSCs might also root from healthy
MSC-induced MM cell death/apoptosis [5]. However,
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in vitro and in vivo remains unknown. The execution of
programmed cell death is a process triggered through
many factors, such as radiation, chemotherapeutic drugs,
and apoptotic signaling, which occurs via intrinsic and ex-
trinsic pathways. Both pathways stimulate an intracellular
cascade of events leading to cell death. The intrinsic path-
way is initiated by mitochondria, whereas the extrinsic
pathway is activated through death receptors that engage
their respective ligands on the surface membrane of target
cells. Fas (DR2/CD95/Apo-1) is a type I cell membrane
protein with an extracellular domain that binds Fas ligand
(Fas-L) and a cytoplasmic domain that transduces the
death signal [19,20]. Fas-L (CD95L/CD178/Apo-1 L) is
a type II cell membrane protein belonging to the TNF
family, which is inducibly expressed in lymphocytes and
constitutively expressed in cells present in immune-
privileged organs [21,22]. Fas-L interacts with its re-
ceptor, Fas, triggering a cascade of subcellular events
culminating in apoptotic cell death [23]. Although Fas/
Fas-L interactions play an important role in inducing
cell apoptosis, it remains unclear whether Fas/Fas-L is
involved in the inhibitory effects of exogenously infused
MSCs on MM cells. The purpose of the present study was
therefore to determine whether MSCs exert apoptosis-
inducing effects on MM cells in vitro and in vivo through
altering Fas/Fas-L expression.
Materials and methods
Multiple myeloma cell line
The 5TGM1 MM cell line used in the present study was
subcloned from a stroma-independent cell line origin-
ally established from parent murine 5 T33 (IgG2bκ)
MMs [24] and grown in long-term suspension culture
in Isocove’s modified Dulbecco’s medium (Invitrogen
Co., Carlsbad, CA, USA) with 10% fetal bovine serum
(Summit Biotechnology, Fort Collins, CO, USA) and
antibiotics. In the tracing experiment, MM cells were
stained with carboxyfluorescein diacetate, succinimidyl
ester (Invitrogen Co.).
Isolation of bone marrow mesenchymal stem cells
Bone marrow cells were flushed from the bone cavity of
femurs and tibias of B6 mice (C57BL/6 J) with 2% heat-
inactivated fetal bovine serum (Equitech-Bio, Kerrville,
TX, USA) in PBS, and MSCs positive for CD73, CD90,
CD105, CD146, CD166, Sca-1 and SSEA-4, but negative
for CD11b, CD31, CD34 and CD45, were obtained as
previously described [25]. The cells with MSC character
were cultured with alpha minimum essential medium
(Invitrogen) supplemented with 20% fetal bovine serum
and 2 mM L-glutamine (Invitrogen) in a humidified
atmosphere of 95% air and 5% CO2 at 37°C for 3 days
before co-culture [26]. Additionally, MSCs, whichhad no Fas-L, were isolated from generalized
lymphoproliferative disease (gld) mice for use in com-
parative experiments. B6 and gld mice in the same back-
ground (B6Smn.C3-Faslgld/J) were purchased from the
Jackson Laboratory.5TGM1 multiple myeloma model and MSC administration
A 5TGM1 MM model was conducted in weight-matched,
8-week-old to 10-week-old female bg-nu/nu-xid mice from
the Jackson Lab (Bar Harbor, ME, USA). The use of ani-
mals for research was approved through the Institutional
Ethics Committee/Institutional Review Board of the
University of Southern California (protocol #10941).
The mice were housed in isolator cages, and autoclaved
chow and acidified water were provided ad libitum.
Disseminated MM was induced through the intravenous
inoculation of 6 × 106 5TGM1 cells in 200 μl PBS in
bg-nu/nu-xid mice through the tail vein (6 × 106/10 g
body weight). After tumor cell inoculation, multiple MM
model mice were randomized to receive the injection of ei-
ther MSCs (once, 1 × 106 MSCs/10 g body weight) via the
tail vein (MSC group) or lymphocyte Peyer’s patch adhe-
sion molecules (L-PAM; weekly, 50 μg/10 g body weight)
in the abdominal cavity (L-PAM group) (Figure 1A) [27].
L-Phenylalanine mustard, or L-PAM, otherwise known as
melphalan, is used as the standard treatment in older MM
patients [28]. MM model mice or original nude mice with-
out any treatments served as positive controls (MM group)
or negative controls (Control group). The 6-week survival
rates of the mice in different groups were compared. After
4 weeks of feeding, the cancroid pearls in the neck, tail root
and abdominal cavity of the mice in different groups were
identified for analysis as described in the literature [26]. For
tissue preparation and immunohistochemistry, the animals
were housed and provided water and a powdered diet until
the time of humane sacrifice.Microcomputed tomography analysis
The cross-sectional volumetric bone mineral density was
measured in right femur diaphysis of the mice in each
group after 4 weeks of feeding (for each group, n = 6).
High-resolution whole-body radiographs of ketamine-
anesthetized mice were obtained with the Inveon
microcomputed tomography system (Siemens AG,
Bensheim, Germany). Using two-dimensional images, a
region of interest in secondary spongiosa was manually
drawn near the endocortical surface, and cancellous
bone morphometric parameters including the bone vol-
ume relative to the tissue volume (percentage) and the
trabecular thickness (millimeters) were assessed. A
trained observer blinded to the composition of the dif-
ferent groups and treatments received analyzed the
number and surface area of radiolucent lesions.
Figure 1 Effect of mesenchymal stem cell infusion in multiple myeloma model mice. (A) Experimental protocol of multiple myeloma (MM)
cell and mesenchymal stem cell (MSC) injection and the design of lymphocyte Peyer’s patch adhesion molecule (LPAM) administration. (B)
Six-week survival rates of animals in different groups (for each group, n = 14). The survival rate in the nontreated MM model group was
dramatically decreased after 3 weeks. The MSC and L-PAM groups had almost the same survival rate, but were higher than the MM group
(P <0.05). Data shown as the mean ± standard deviation (SD) of three parallel experiments. *P <0.05 versus MM group. (C) Comparison of clinical
findings in each group. The number (left) and size (right) of cancroid pearls in the neck, root of tail and abdominal cavity are shown as column
graphs (top panel). Data shown as mean ± SD for three parallel experiments. *P <0.05 versus MSC group; #P <0.05 versus L-PAM group. Lower
panel: representative photograph of typical cancroid pearls in the base of the tail (bar = 5 mm). (D) Comparison of bone resorption in lumbus
and collum femoris in each group. Radiographs of lumbus and collum femoris at 3 weeks after MM cell injection, and the bone density in each
group was analyzed. Data shown as mean ± SD for four parallel experiments. *P <0.05 versus MM group; #P <0.05 versus L-PAM group. (E)
Myeloma cell metastasis in the lungs and kidneys in each group. Data shown as mean ± SD for three parallel experiments. *P <0.05 versus MSC
group. Left panels: light micrographs of the lungs and kidneys (hematoxylin and eosin staining, bar = 100 μm). Con, control.
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Tissue preparation was performed as previously described
[29]. The mice were sacrificed after 4 weeks of feeding.
The samples were immersed in 4% paraformaldehyde for
24 hours and embedded in 20% sucrose overnight at 4°
C. The samples were immersed in O.C.T. compound
(Sakura, Tokyo, Japan) for 2 hours at 4°C and cut into
6 μm thick bucco-palatal sections using a cryostat
at −20°C. For immunofluorescence staining, thesections were blocked for 30 minutes with 10% normal
goat serum and incubated overnight with fluorescein
isothiocyanate-conjugated polyclonal rabbit Sca-1 IgG
(1:100; Vector Laboratories, Burlingame, CA, USA),
7AAD and Annexin V (Apoptosis Detection Kit; BD
Biosciences, Franklin Lakes, NJ, USA) at 4°C. The other
sections were stained with hematoxylin and eosin and
photographed using a light microscope. In addition, for
terminal deoxynucleotidyl transferase-mediated UTP
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(Millipore Co., Billerica, MA, USA) was used in accord-
ance with the manufacturer’s instructions.
Cell culture conditions
To determinate the in vitro cellular effects of MSCs on
MM and 5TGM1 MM cells were co-cultured with MSCs
directly or under Transwell® culture conditions. For direct
co-culture, MM cells were plated at 5 × 105/ml with or
without 5 × 105/ml MSCs for 0, 6, 12 or 24 hours. For
in-direct co-culture, Transwell® culture was used. Briefly,
the upper chamber (0.5 ml culture medium) contained
0.5 × 105 MSCs, and the bottom chamber (1.5 ml medium)
contained either the same number or 5 to 10 times that of
MM cells. The Transwell® culture without MSCs in the
upper chamber served as the control. In the conditioned
culture medium, 0.5 × 105 MSCs were cultured for 3 days.
The supernatant was harvested, added to the MM cultures,
and then cultured for 0, 6, 12 or 24 hours.
Flow cytometric analysis
After the MM cells were co-cultured with MSCs for 0,
6, 12 and 24 hours under Transwell® culture conditions,
the cells were harvested, washed in PBS and incubated
with Annexin-V– fluorescein isothiocyanate and 7AAD-
PerCP for 15 minutes at room temperature in the dark.
Apoptosis was analyzed on a BD FACSCalibur™ flow
cytometer (BD Biosciences, San Jose, CA, USA), as de-
scribed in the literature [30].
Western blotting
Total cell lysates for western blots were prepared after lys-
ing cell pellets in radioimmunoprecipitation assay buffer.
The lysates were separated through 7.5% SDS-PAGE,
transferred to Immobilon™-P nitrocellulose membranes
(Millipore, Inc.) and immunoblotted with Fas (1:100) or
Fas-L (1:100) antibodies at 4°C overnight. The membranes
were subsequently incubated with horseradish peroxidase-
conjugated anti-rabbit IgG (1:10,000; Santa Cruz
Biosciences, Santa Cruz, CA, USA) for 1 hour, followed by
enhancement with a SuperSignal® West Pico Chemilumin-
escent Substrate (Thermo, Rockford, IL, USA). The bands
were detected on BIOMAX MR film (Kodak, Rochester,
NY, USA). Each membrane was also stripped using a strip-
ping buffer (Thermo) and reprobed with anti-β-actin anti-
body to quantify the amount of loaded protein.
Immunofluorescence staining for multiple myeloma cells
or MSCs
MM cells and MSCs co-cultured on dishes were fixed in
4% formaldehyde for 10 minutes. For fluorescence
staining, the samples were treated in 0.5% (V/V) Triton
X-100 (Novocastra Laboratories Ltd, Newcastle, UK) for 3
minutes and incubated with Annexin V/7AAD. The othercells were blocked with 10% normal goat serum for 30 mi-
nutes at 37°C and incubated overnight at 4°C with anti-Fas
(1:100; Chemicon International Inc. Temecula, CA,
USA) or anti-Fas-L (1:100; Chemicon International
Inc.) antibodies. The samples were incubated with
tetramethylrhodamine isothiocynate-conjugated or fluores-
cein isothiocyanate-conjugated secondary antibodies for 2
hours at 37°C. Imaging was performed using an Axiotech
Microscope (Carl Zeiss Co. Ltd, Göttingen, Germany).
Statistical analysis
Data are expressed as mean ± standard deviation for two
to four parallel experiments repeated separately. One-way
analysis of variance and Fisher’s least-significant difference
tests were performed. P <0.05 was considered statistically
significant. The experiments were performed in triplicate
and repeated twice or more to verify the results.
Results
Effects of MSC infusion on multiple myeloma model mice
We investigated the 6-week survival rates of mice in
each group (for each group, n = 14). The effect of MSC
administration on the 6-week survival rates of MM
model mice is shown in Figure 1B. The survival rate of
MM model mice without MSC or L-PAM treatment
(MM group) dramatically decreased until all mice died
after 6 weeks of feeding. MM model mice with MSC
(MSC group) or L-PAM (L-PAM group) administration
showed no difference in the survival rate during the 6-week
observation period (P >0.05). Although the survival rate of
mice in the MSC group or the L-PAM group was lower
than in the Control group (original nude mice without MM
cell injection) (P <0.05), the administration of either MSCs
or L-PAM achieved prolonged survival compared with the
MM group (P <0.05). No animal in the negative control
group died (the original nude mice without any treatments)
after 6 weeks of feeding.
The number and size of cancroid pearls were compared
among the four groups (for each group, n = 14) after 4
weeks of feeding (Figure 1C). No cancroid pearls were
identified in the negative control group (Control group),
but significant differences in the number and size of the
pearls were observed between the MSC and MM groups
(P <0.05). Although the number of pearls showed no
significant difference, the size of the pearls in the L-PAM
group was smaller compared with the MM group (P <0.05).
These data indicate that MSC administration inhibits both
the number and the size of cancroid pearls in MM model
mice, while L-PAM administration inhibits only the size of
cancroid pearls.
Furthermore, bone resorption in the lumbus and collum
femoris of mice in different groups was examined and
statistically analyzed through microcomputed tomography
after 4 weeks of feeding (for each group, n = 3) (Figure 1D).
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femoris of animals in the MM group was much lower
compared with the BD in the MSC, L-PAM, or Control
groups (P < 0.05). Although lower than the Control group
(P <0.05), no significant differences were observed between
the two treated groups (P >0.05).
In addition, MM cell metastasis was determined and
quantified in the lungs and kidneys of MM model mice
after 4 weeks of feeding (for each group, n = 5) (Figure 1E).
The rate of metastasis in the lung tissue obtained from
mice in the MSC group was much lower compared with
either the MM or the L-PAM groups (P <0.05). Similarly,
no significant difference was observed among the MM,
MSC, and L-PAM groups in kidney tissue, although the
metastasis rate in the MSC group was lowest (P <0.05).
Effects of MSCs on multiple myeloma cells under co-culture
conditions
First, we designed three testing co-culture groups, where
the number of MM cells was equal to or five to 10 times
greater than that of MSCs. MM cells without MSC co-
culture served as the control. In the control group, the MM
cell number increased 2.5-fold over the initial cell number
at 24 hours after co-culture. When the initial number of
MM cells was equal to or five times greater than that of
MSCs, the inhibitory effect of MSCs on MM cell increase
was apparent. However, no significant MM cell increase
was observed when the number of MM cells was 10 times
the number of MSCs (Figure 2A).
To determine whether the reduction was induced
through MM cell apoptosis, caspase-3 and caspase-8 ex-
pression in MMs was determined through western blot-
ting. The increased expression of cleaved caspase-3 and
caspase-8 was observed in most MM cells after 12 hours of
co-culture (Figure 2B). The cleaved caspase-3 and caspase-
8 expression in MM cells without co-culture with MSCs
was fixed, while the expression of cleaved caspase-3 and
caspase-8 in MM cells co-cultured with MSCs was slightly
increased. Furthermore, the apoptotic rate of MM cells
was examined using fluorescence-activated cell sorting
and Annexin V and 7AAD immunofluorescence. We
observed that the apoptotic rate of MM cells, determined
and quantified through fluorescence-activated cell sorting
analysis, was dramatically changed at 12 hours after
co-culture with MSCs (P <0.05) (Figure 2C). In the
case of immunofluorescence, the number of positive
apoptotic markers in MM cells significantly increased
after 6 hours of co-culture (P <0.05) (Figure 2D).
Influence of Fas/Fas ligand pathway on multiple myeloma
cell apoptosis
Next, we investigated the different conditions of co-culture
with MSCs to confirm the necessity of direct contact
between MSCs and MM cells for the induction of MM cellapoptosis. Only the direct co-culture group, which shows
direct contact between MM cells and MSCs, exhibited a
strong inhibitory effect on MM cell growth (P <0.05)
(Figure 3A). In addition, the expression of Fas in MM
cells and Fas-L in MSCs, determined through western
blotting, increased at 12 and 24 hours (P <0.05) (Figure 3B).
The data for immunofluorescence staining showed results
similar to those of the western blot analysis (Figure 3C).
MSCs from gld mice, which had no Fas-L, and aspirin-
treated MSCs, which had high Fas-L, were used to confirm
that the enhancement of Fas-L in MSCs increased the apop-
tosis of MM cells. Aspirin treatment showed the enhanced
expression of Fas-L in MSCs (Figure 4A). A reduction in the
number of MM cells co-cultured with aspirin-treated
MSCs was less than that in the normal co-cultured group
(co-cultured with normal MSCs) at 12 hours (P <0.05)
(Figure 4B). However, co-culture with the MSCs obtained
from gld mice had little influence on MM cell growth.
Furthermore, the expression of caspase-3 and caspase-8 in
MM cells co-cultured with aspirin-treated MSCs was
significantly increased after 12 hours. Under these con-
ditions, the protein expression of cleaved caspase-3 and
caspase-8 was reduced after 12 hours. In the case of the
gld group, the expression of these proteins remained
unchanged (Figure 4C). The rate of apoptotic cell death
was further investigated using fluorescence-activated
cell sorting (Figure 4D) and immunofluorescence with
Annexin V/7AAD (Figure 4E). Aspirin-treated MSCs
showed a greater effect on MM cells than normal MSCs
(control group) (P <0.05), and MSCs obtained from gld
mice showed effects similar to those of normal MSCs.Effects of MSCs with highly expressed Fas ligand on the
multiple myeloma model mice
The MSCs obtained from normal, gld or aspirin-treated
mice were used to examine the 5-week survival rates of
the MM model mice. The survival rate in the MM model
mice treated with aspirin was much higher compared with
normal MSC-treated mice (P <0.05). Interestingly, the
MSCs obtained from the gld mice showed a reduced
survival rate (Figure 5A). Furthermore, the number and
the size of cancroid pearls were compared among all
groups, and both the number and size in the aspirin-
treated group were lower compared with the normal group.
However, the gld treated group showed a significantly larger
cancroid pearl size compared with the MM model mice
without MSC treatment (MM group), although the number
of pearls in the MSC gld treated group was less than that in
the MM group (Figure 5B). Figure 5C showed the distribu-
tion of cancroid pearl size in the MM model mice in each
group. Moreover, the presence of MSCs and the apoptosis
of MM cells in the pearls of the MM model mice were ob-
served through immunofluorescence and TUNEL staining.
Figure 2 Relationship between multiple myeloma cells and mesenchymal stem cells under co-culture conditions. (A) Multiplication of
multiple myeloma (MM) cells under co-culture with mesenchymal stem cells (MSCs). (B) Western blot analyses of apoptosis markers. Expression
levels of cleaved caspase-3 and caspase-8 in MM cells with or without co-culture with MSCs were analyzed through western blotting at 0, 6, 12,
and 24 hours (lower table arranged to numerical value from upper data). (C) Apoptotic analysis through fluorescence-activated cell sorting (FACS)
(x axis, Annexin V; y axis, 7AAD-positive cells). Apoptosis of MM cells with or without co-culture with MSCs was detected and quantified through
FACS at 0, 6, 12, and 24 hours (lower table arranged from upper data). Data presented as mean ± standard deviation (SD) for two parallel
experiments. #P <0.05 versus the control group (Cont.). (D) Rate of apoptotic MM cells under co-culture with MSCs. The microscope pictures
represent typical reactions of MM cells in fluorescence staining, where MM cells were prestained for carboxyfluorescein diacetate, succinimidyl
ester (CFSE; green) and apoptosis markers using Annexin V and 7AAD (red). Lower table arranged to numerical value from upper data. Data
presented as mean ± SD for two parallel experiments. #P <0.05 versus the control group (Cont.). DAPI, 4′,6-diamidino-2-phenylindole.
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groups (Figure 5D).
Discussion
MM is a malignancy of antibody-secreting plasma cells,
where B-cell plasmacytomas stimulate osteoclast activity,
and hence bone resorption, resulting in progressive
osteolytic lesions [18]. Based on studies concerning the
pathogenic role of autoantibodies in MM diseases, re-
cent advances in this field suggest a more central role
for B cells in the maintenance of the disease process be-
yond their roles as precursors for (auto)antibody-produ-
cing plasma cells [31]. Particularly, a number of surface
molecules and subsequent downstream signalingpathways are involved in the regulation of MM-related
bone destroying events, in which bone resorption and
formation are no longer balanced as a consequence of
the increased activity of osteoclasts, but rather the osteo-
blast activity is reduced, leading to an uncoupled, or se-
verely imbalanced, bone remodeling process [2]. Clinical
data have shown that MM patients with advanced bone
lesions might show a reduction of bone formation
markers, such as alkaline phosphatase and osteocalcin,
together with increased bone resorption markers, such
as receptor activator of nuclear factor κB ligand (RANKL)
and C-terminal cross-linked telopeptide of type I collagen
[32]. Similarly, marked osteoblastopenia and reduced
bone formation have also been reported in murine
Figure 3 Fas and Fas ligand analysis in multiple myeloma cells and mesenchymal stem cells under co-culture. (A) Multiplication of
multiple myeloma (MM) cells under different co-culture conditions with mesenchymal stem cells (MSCs) (Cont., MM single culture; C-medium,
MM culture with conditioned medium from MSC culture; Trans-well, indirect co-culture between MM and MSC; Co-cul, direct culture between
MM and MSC). Each data point represents the mean ± standard deviation (SD) of two parallel experiments. #P <0.05 versus the control group
(Cont.). (B) Western blotting analyses of the expression levels of Fas and Fas ligand (Fas-L) in MM cells and MSCs under co-culture condition for 0,
6, 12, and 24 hours. (C), (D) The rates of Fas-positive or Fas-L-positive cells were determined through immunofluorescence staining. (C) MM cells
were prestained for carboxyfluorescein diacetate, succinimidyl ester (CFSE; green) and then post-stained for Fas (red). (D) MSCs were stained for
Scar-1 (green) and subsequently stained for Fas-L (red). Bar = 300 μm. Numbers of Fas-positive MM cells and Fas-L-positive MSCs are shown. Data
presented as the mean ± SD for two parallel experiments. #P <0.05 versus the control group (Cont.). DAPI, 4′,6-diamidino-2-phenylindole.
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http://stemcellres.com/content/4/5/111models of MM bone disease [33]. These studies demon-
strate that MM cells suppress osteoblast formation and
differentiation, and consequently inhibit bone formation.
Recent mounting evidence indicates that MM cells
suppress osteoblastogenesis through contact-dependent
cell–cell interaction [7,34] and the production of osteoblast-
inactivating factors including Wnt inhibitors, such as
dickkopf-1 [10] and secreted frizzled-related protein 2 [35],
and cytokines, such as CCL3 (also known as macrophage
inflammatory protein-1 alpha) [11], hepatocyte growth
factor, and IL-3/6 [18]. Osteolytic lesions in MM are only
observed adjacent to intramedullary plasma cell foci or
plasmacytomas, supporting the idea that MM cells might
secrete factors that promote the activation of osteoclasts
and the inactivation of osteoblast function to replace bone
loss [36]. More effective approaches to cure MM-related
bone disease, in addition to the correction of osteoblastfunction, should therefore be reflected in therapeutic
modalities aimed at inducing MM cell death.
Researchers in the stem cell field are working to translate
the knowledge gained from stem cell biology and function
into therapeutic breakthroughs and applications. It is well
known that osteoblasts originate primarily from MSCs and
are responsible for bone matrix synthesis through the se-
cretion of collagen, which forms strands called osteoid [37].
Osteoclast activity is regulated through the expression of
cytokines, such as receptor activator of RANKL, which acti-
vates osteoclast differentiation, and osteoprotegerin, which
acts as a decoy receptor and inhibits RANKL [38]. Based
on this knowledge, MSC-based cytotherapy has established
a novel concept for the treatment of MM-related bone dis-
ease [39]. Recently, Li and colleagues demonstrated that
both systemic and intrabone cytotherapeutic strategies were
effective and clinically applicable for treating MM-related
Figure 4 Effects of Fas ligand levels in mesenchymal stem cells on multiple myeloma cells under co-culture. (A) Comparison of Fas
ligand (Fas-L) expression in mesenchymal stem cells (MSCs) after aspirin treatment. (B) Multiplication of multiple myeloma (MM) cells under
co-culture condition with MSCs that express different levels of Fas-L. For the graph, the number of MM co-cultured without MSCs (Cont.), with
normal MSCs (Co-cul), with MSCs from generalized lymphoproliferative disease mice (Co-cul(gld)) or with MSCs treated with any aspirin
(Co-cul(Asp)) were counted after 0, 6, 12 or 24 hours. (C) Apoptotic analysis of MM cells under co-culture condition with MSCs expressing
different levels of Fas-L (detected and quantified through fluorescence-activated cell sorting (FACS): x axis, Annexin V; y axis, 7AAD-positive cells).
Data presented as mean ± standard deviation (SD) for two parallel experiments. #P <0.05 versus Con. (D) Expression levels of cleaved caspase-3
in MM cells with or without co-cultured MSCs (expressing different levels of Fas-L) at 0, 6, 12, and 24 hours. (E) Rates of apoptotic MM under
co-culture with MSCs (expressing different levels of Fas-L). Data presented as mean ± SD for two parallel experiments. #P <0.05 versus the control
group (Con.). CFSE, carboxyfluorescein diacetate, succinimidyl ester; DAPI, 4′,6-diamidino-2-phenylindole.
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MSCs restrained MM disease progression through the abil-
ity of MSCs to traffic to myelomatous bone and survive for
a short period of time [5]. Intrabone injections of MSCs,
however, not only inhibited tumor growth in the bone with
active MM but also effectively promoted bone formation
during disease, remission and delayed MM relapse. Al-
though this study provides a proof-of-concept for the use
of MSC cytotherapy to treat large, unhealed, osteolytic le-
sions and for the systemic inhibition of MM bone disease,
the mechanisms of action by which MSC cytotherapy stim-
ulates bone formation and inhibits MM-induced bone
tumor growth, are, however, only partially understood [15].
Whether MSCs inhibit or promote cancer growth has de-
veloped into a controversy reflected in concern over the
use of MSCs, which exhibit a propensity to home totumors. Once resident in the tumor microenvironment,
these cells support tumor growth and spread [14], although
the ability of cultured MSCs to support long-term
growth of primary MM cells is often limited and not repro-
ducible [40,41]. Therefore, understanding the in vivo mi-
lieu in which MSCs either inhibit or enhance MM cell
survival and metastasis is crucial both to safely develop
MSCs as a therapeutic tool and to advance our under-
standing of the role of tumor stroma in carcinogenesis
[16,17]. Moreover, we still do not have a general con-
sensus of what defines these MSCs; the polarization of
MSCs into a proinflammatory or an immunosuppressive
phenotype showing reversed effects on tumor growth has
been observed [17,42]. Similarly, in our present study, Fas-
Lhigh MSCs showed significant inhibition, while Fas-Lnull
MSCs showed promoted MM growth, suggesting that the
Figure 5 Effect of mesenchymal stem cells with highly activated Fas ligand on multiple myeloma model mice. (A) Five-week survival
rates of multiple myeloma (MM) model mice. (B) Comparison of the number (left) and size (right) of cancroid pearls in MM model mice after
treatment with mesenchymal stem cells (MSCs) expressing different levels of Fas ligand (Fas-L). Data presented as mean ± standard deviation
(SD) for three parallel experiments. *P <0.05 versus MSC group; #P <0.05 versus the control group. Right panel: representative photograph of
typical cancroid pearls at the base of the tail (bar = 5 mm). (C) Distribution of cancroid pearl size in the four test groups (n = 14). (D) Apoptosis
of MM cells in MM model mice. The pearls in each group were triple-stained for 4′,6-diamidino-2-phenylindole ( blue), Scar-1 (green) and Annexin
V/7AAD (red). All groups treated with MSCs had Scar-1-positive cells in the pearls. However, the positive reactions of apoptosis marker in the MSC
(gld) group were much lower than those observed in other groups. The MSC(Asp) group had the highest number of reactions among all groups
(bar = 5μm). Lower panels stained through the terminal deoxynucleotidyl transferase-mediated UTP nick-end labeling (TUNEL) assay. Positive
reactions were observed in both MSC and MSC(Asp) groups. ASP, aspirin; Con, control; gld, generalized lymphoproliferative disease.
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part, the effect of MSCs on cancer growth.
Recent findings suggest that the overexpression of
growth differentiation factor 15 in bone marrow
MSCs occurs widely in patients with MM, and tumor
microenvironment-derived growth differentiation factor 15
is a key survival and chemoprotective factor for MM cells,
indicating that the behavior of MSCs might be principally
determined by the surrounding environment [43]. The two
side effects of MSCs on MM cells identified from previous
studies are therefore basically acceptable. To further clarify
the role of healthy MSCs in MM metastasis and apoptosis,
we examined whether outside-infused MSCs would have
therapeutic effects on MM cells in mice under co-culture
conditions. The data obtained in the present study are
clearly inconsistent with some reports, which have indi-
cated that murine and human MSCs promote breast and
coronal cancer growth and metastasis [44,45]. Interestingly,
Ma and colleagues showed that human umbilical cord
MSCs significantly inhibited the growth of breast cancer
cells in vitro and in vivo [46]. Furthermore, the ability
of cytotherapy through placenta-derived adherent cells
to impact bone remodeling and increase bone formation innonmyelomatous SCID-rab mice has been demonstrated
[15]. Intralesional mesenchymal cell cytotherapy also
resulted in inhibiting growth of H929 MM cells and
primary MM cells categorized through global gene expres-
sion as high risk. Moreover, placenta-derived adherent cells
had no effect on the subcutaneous growth of H929 MM
cells in SCID mice, and did not confer a growth ad-
vantage to MM cells co-cultured with placenta-derived
adherent cells or supportive MSCs [47]. Recently, adipose-
derived MSCs, engineered to express the pro-apoptotic
ligand TRAIL (also known as TNFSF10), killed MM cells
and migrated towards MM cells in vitro [48]. These re-
sults, together with data in the present study, support the
idea that certain phenotypes of MSCs exhibit inhibitory
effects on MM cells, such that the anti-myeloma activity
of MSCs can be harnessed or enhanced, for example, via
gene-modified approaches.
It has been well recognized that MSC therapy poten-
tially offers novel therapeutic modalities that are trans-
latable for clinical treatment of a large variety of
pathological conditions or diseases [49]. This develop-
ment is also true for clinically managing and combating
cancer, as MSCs play a central role in the pathogenesis
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thus reduces solid tumor growth in mice due to an in-
hibition of tumor cell proliferation, probably resulting
from deep modifications of the tumor angiogenesis, regard-
less of the tumor model and mode of MSC injection [51].
Clinically, current evidence suggests that cytotherapy mark-
edly increases the proportion of MSCs in bone of MM pa-
tients, at least for a short period of time [5,15]. As
deduced from in vitro studies, during this short time,
the injected MSCs probably interact with endogenous
osteoblast precursors and secrete factors that induce their
differentiation into bone-building osteoblasts, while simul-
taneously directly interactions with osteoclast precursors to
secrete factors that attenuate the formation of bone-
resorbing osteoclasts [15]. Notably, similar to osteo-
blasts, MSCs might produce a high level of decorin pro-
tein, which inhibits osteoclast formation and promotes
osteoblast differentiation [8]. Following the identifica-
tion of the potential for MSCs to enhance engraftment
of hematopoietic stem cells, increase osteoblast activity
and suppress osteoclast activity [52], MSCs recruited
hematopoietic elements that inhibit inflammatory condi-
tions typically associated with MM growth in bone [15].
Along with recent findings in this field [17,42], it is specu-
lated that MM progression is restrained, directly and indir-
ectly, through anti-inflammatory factors produced by the
injected MSCs or endogenous cells recruited to myeloma-
tous bone after cytotherapy. The findings that MSCs
express high levels of anti-inflammatory and antineoplastic
factors, such as SERPINF1 and decorin, support this
concept [5]. Decorin also attenuates MM cell growth [5].
Although certain soluble factors produced by MSCs might
mediate part of their therapeutic activities, cytotherapy at
a remote site (subcutaneous) was found to have no effect
on MM bone disease or growth [15], suggesting that MSCs
must be present in bone marrow to elicit their antimyeloma
effects. Indeed, only MSCs injected directly into bone might
efficiently induce an antimyeloma environment. Systemic-
ally injected MSCs significantly promote bone formation or
restrain MM growth because relatively few of those MSCs
can transmigrate and traffic to bone [5]. Recent results,
however, also suggest that MSCs might be attracted to bone
through MM cells or conditions induced through MM or
melphalan treatment. More importantly, MSCs might be
cleared in various tissues, but exhibit higher survival rates
in the implanted bone or lymph nodes and therefore could
be detected in these tissues at 2 to 3 days after intravenous
or intracardiac injections, respectively [5]. The accumula-
tion of MSCs in lymph nodes, however, might partially ex-
plain their immunomodulatory properties. In fact, evidence
suggests that intravenously injected MSCs might localize
in the lymph nodes of experimental mouse models of
autoimmunity [53,54]. This body of work might also ex-
plain the fewer numbers and smaller sizes of cancroidpearls in the neck and root tail of the MSC-treated MM
mice in the present study.
Recent studies have revealed that exogenously injected
MSCs were not detectable in vivo for long periods of
time; the majority of these cells disappeared within 3 to
5 weeks [15,55]. Clinically, this phenomenon might be
advantageous because it limits the duration of the inter-
vention, and these observations support the notion that
most of their activities are mediated through the touch-
and-go mechanisms of bystander cells, although proof
of such evanescence is thus far not well defined [5,56].
In support of using allogeneic MSCs for MM, Li and
colleagues recently demonstrated that intralesionally
injected human placenta mesenchymal cells exert similar
therapeutic effects in SCID-rab mice [15]. Together, these
studies raise an intriguing possibility: if we could under-
stand how MSCs induce MM cell death, then perhaps we
could exogenously manipulate MSCs to effectively man-
age MM and saved a large number of lives. An important,
yet unelucidated, question raised by our study is whether a
majority of MSCs transmigrate to the myelomatous bone
to kill MM cells after intravenous injection, or traffic to
lymph nodes to exert inhibitory effects on MM cells via the
secretion of anti-inflammatory factors.
The potential role of molecules involved in altered
B-cell longevity, particularly those involved in apoptosis
(for example, Fas/Fas-L modulators), and those that might
alter activation thresholds of B cells in the develop-
ment of autoimmunity, might contribute to the clinical
management of MM [27,31]. Unfortunately, however,
we still know relatively little about this issue. Recently,
a number of studies have reported the effects of the
Fas/Fas-L pathway on fluoride-induced or melatonin-
induced cell apoptosis [57,58]. In the present study, it
was shown that MSCs counterattack MM cells using
the same mechanism as observed in other cancer cells;
namely, Fas-mediated apoptosis. Fas and Fas-L are co-
expressed on primary MSCs that might kill co-cultured
MM cells. Co-expression of Fas and Fas-L by MSCs calls
into question the functionality of the extrinsic apoptosis
pathway in these cells. Although Mazar and colleagues
detected Fas expression on MSCs, stimulation of Fas with
different concentrations of anti-Fas antibody did not
result in any apoptotic response [23]. At this stage, we
were not able to identify the exact molecular mechan-
ism of Fas-mediated pathway inactivation in MSCs, but
we might narrow this process to events between Fas
protein trimerization and caspase-8 activation. As previ-
ously demonstrated, caspase-8 deficiency resulted in the
inhibition of apoptosis of Jurkat cells, and blocking with
Fas Fc protein prevented bone marrow MSC-induced
apoptosis in 80% [23]. Other studies have shown that the
transformation of the intracellular domain of Fas protein
expressed in human MSCs prevents the trimerization of
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way activation [59]. MM cells might thus be susceptible to
the induction of apoptosis through MSCs.
Briefly, we showed that MSCs act directly on MM
cells, inhibiting proliferation. MSC-induced apoptosis in
MM cells is evidenced by an increase in the Annexin/
7AAD-positive cell population. Most of this effect can
be attributed to the Fas/Fas-L pathway. These results
confirm and extend previous reports [60,61]. In our MM
model, the activation of both caspase-3 and caspase-8 was
observed, suggesting that two main pathways of procaspase
activation – the intrinsic mitochondrial pathway and
the extrinsic death receptor pathway – are both in-
volved in MSC-induced apoptosis of MM. Having de-
termined the effects of MSCs activated through aspirin
(with highly activated Fas-L) in the MM model mice,
these MSCs resulted in a more effective clinical outcome
compared with MSCs from the gld mice. We thus expected
that MSCs with high Fas-L expression would be extremely
effective in inhibiting MM growth and metastasis. These re-
sults are consistent in principle with those of another study,
showing that infused MSCs moved immediately to the
tumor site [62]. However, the positive TUNEL reactions
within MSCs from the gld mice were much lower than
the others, suggesting that MSCs without Fas-L have no
capacity to kill MM cells.
Conclusion
Fas-L is expressed on MSCs to induce MM cell apoptosis
under co-culture conditions. Furthermore, Fas-L activated
through aspirin effectively inhibits the growth and metas-
tasis of MMs in vitro and in vivo. Our results showed the
additive or synergistic anti-MM activity of MSCs with
highly activated Fas-L, measured on the basis of cell
growth, apoptosis, and modest survival improvement of
MM-bearing mice, indicating that the levels of Fas-L ex-
pression in MSCs determine, at least partially, the effect of
MSCs on cancer growth. Our finding has opened up a
new way of thinking about the effect of MSCs against
MM cells and a new way of moving forward. Further re-
search should aim at improving the trafficking of infused
MSCs to myelomatous bone, clarifying and increasing the
anti-inflammatory therapeutic potential of these cells dur-
ing active disease or maintenance therapy compared with
the typical administration of drugs, such as L-PAM.
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